Employing tumor hypoxia for oncolytic therapy in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 10, Issue 4, 2005, Pages 311-318

  Chun, Yun Shin ^a   Adusumilli, Prasad S ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene therapy; Herpes simplex virus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA RESPONSIVE ELEMENT; MITOMYCIN C; PROGESTERONE RECEPTOR; PROTEIN INHIBITOR; PROTEIN P53; RABIES VACCINE; RIBONUCLEOTIDE REDUCTASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL MOLECULE TRANSPORT AGENT; TAMOXIFEN; THIOREDOXIN; TIRAPAZAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FATIGUE; GENE EXPRESSION; GENE MUTATION; GENETIC ENGINEERING; HERPES SIMPLEX; HUMAN; HYPOXEMIA; METASTASIS; MUSCLE CRAMP; NONHUMAN; OXYGEN CONCENTRATION; PROTEIN FUNCTION; TUMOR CELL; TUMOR CELL DESTRUCTION; UPREGULATION; UTERINE CERVIX CANCER; VIRAL GENE THERAPY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANOXIA; BREAST NEOPLASMS; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 33747484488     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-006-9004-6     Document Type: Article

References (67)

1. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59(1):41-8.
2. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 2001;18(4):243-59.
3. Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, et al. Health-related quality of life in survivors of locally advanced breast cancer: An international randomised controlled phase III trial. Lancet Oncol 2005;6(5):287-94.
4. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003;21(17):3244-8.
5. Hohenberger P, Felgner C, Haensch W, Schlag PM. Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 1998;48(2):97-106.
6. Pin RH, Reinblatt M, Fong Y. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. Surgery 2004;136(2):199-204.
7. Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 2005;12(8):647-54.
8. Liu RB, Rabkin SD. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer. Chin Med J 2005;118(4):307-12.
9. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 2005;65(4):1532-40.
10. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 2004;15(6):988-9.
11. Reinblatt M, Pin RH, Federoff HJ, Fong Y. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg 2004;239(6):892-9.
12. De Pace NG. Sulla scomparsa di un enorme cancro vegetatnte del collo dell'utero senza cura chirugica. Ginecologia 1912;9:82.
13. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2(7715):105-6.
14. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet 1981;1(8229):1112.
15. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252(5007):854-6.
16. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105(7):841-6.
17. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996;93(21):11307-12.
18. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250(4985):1262-6.
19. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002;9(11):935-45.
20. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 2002;13(10):1213-23.
21. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13(11):1325-34.
22. Mullerad M, Bochner BH, Adusumilli PS, Bhargava A, Kikuchi E, Hui-Ni C, et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol 2005;174(2):741-6.
23. Adusumilli PS, Stiles BM, Chan MK, Chou TC, Wong RJ, Rusch VW, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg 2005;80(2):409-16.
24. Fong Y, Jarnagin WR, Guilfoyle B, Tufaro F, Haag N, Glasschroeder B, et al. Results of a phase 1, dose-escalating study of the safety, tolerability, and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, NV1020, in subjects with hepatic colorectal metastases. American Society of Clinical Oncology. 2005. Abstract #242
25. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000;7(10):867-74.
26. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-85.
27. Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res 2001;61(7):3009-15.
28. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995;55(17):3902-7.
29. Erdem O, Dursun A, Coskun U, Gunel N. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori 2005;91(1):46-52.
30. Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL, Jr., et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 2005;103(11):2252-60.
31. Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004;64(7):2561-7.
32. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3(3):223-32.
33. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Modern Pathology 2005;18(10):1295-1304.
34. Ruan H, Su H, Hu L, Lamborn KR, Kan YW, Deen DF. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia (New York) 2001;3(3):255-63.
35. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51(12):3316-22.
36. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol, Biol, Phys 1993;26(4):631-6.
37. Kurebayashi J, Otsuki T, Moriya T, Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001;92(10):1093-101.
38. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93(4):309-14.
39. Bos R, van der GP, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97(6):1573-81.
40. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8(6):1831-7.
41. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996 Oct;271(4 Pt 1):C1172-80.
42. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92(12):5510-4.
43. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nature Reviews; 2003 Drug Discovery 2(10):803-11.
44. Binley K, Iqball S, Kingsman A, Kingsman S, Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999;6(10):1721-7.
45. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti-Cancer Drug Des 1998;13(6):519-28.
46. Johnson CA, Kilpatrick D, von RR, Langer C, Graham MA, Greenslade D, et al. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 1997;15(2):773-80.
47. Ara G, Coleman CN, Teicher BA. SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. Cancer Lett 1994;85(2):195-203.
48. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271(30):17771-8.
49. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6(12):1335-40.
50. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005;65(2):605-12.
51. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62(17):5089-95.
52. Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004;18(9):1001-3.
53. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000;7(6):493-8.
54. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8(23):1801-7.
55. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994;269(6):4355-9.
56. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 1991;88(13):5680-4.
57. Boast K, Binley K, Iqball S, Price T, Spearman H, Kingsman S, et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999;10(13):2197-208.
58. Dachs GU, Greco O, Tozer GM. Targeting cancer with gene therapy using hypoxia as a stimulus. Methods Mol Med 2004;90:371-87.
59. Liebermann DA, Hoffman B. Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia 2002;16(4):527-41.
60. Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat Med 2001;7(7):859-63.
61. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43(1):169-87.
62. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004;64(17):6101-8.
63. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6(8):879-85.
64. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90.
65. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Reviews 2003;Cancer. 3(10):721-32.
66. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1(9):938-43.
67. Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 2004;85(1):42-7.